echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > These API manufacturers may benefit from the promotion of bulk procurement to the whole country

    These API manufacturers may benefit from the promotion of bulk procurement to the whole country

    • Last Update: 2019-07-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [industry trends of pharmaceutical network] recently, it was reported that the second round of centralized procurement will implement national linkage, but the specific situation has not been disclosed According to the industry, the quotation of the second round of centralized purchase is low price and can be selected by three enterprises After the low price is set, other manufacturers can decide whether to follow the bid There is no doubt that, for the winning manufacturer, although the price is low, the market is very broad On the other hand, the demand for upstream API of these winning enterprises will inevitably continue to expand, and API manufacturers may benefit The author understands that the winning enterprises have strict production requirements and are subject to the key supervision of the whole industrial chain, so as to ensure that the products they produce reach the hands of consumers are safe and effective Therefore, it is not the API manufacturers that can get a piece of it "In this case, only enterprises with upstream API production can have more bargaining space, while enterprises with low-level production can not be compared with API enterprises at all," the industry said It is reported that there are 1500 kinds of APIs in China, of which only one enterprise has the approval qualification to produce 50 kinds of APIs, only two enterprises can produce 44 kinds of APIs, 10% of APIs can only be produced by single digit manufacturers, and another API can correspond to 169 preparation enterprises From the above data, it is not difficult to see that API enterprises with production qualification have a very broad market, and the competition is not big, and they can obtain good profits in the long term But with this time, the industry is more worried about the industry is very common and frequent problems, that is, monopoly The problem of monopoly of APIs has been common The direct consequence is that downstream pharmaceutical manufacturers cannot buy APIs and need to buy some products at a high price The cost of purchasing APIs for large-scale enterprises is rising, and small and medium-sized pharmaceutical manufacturers are likely to stop production and even close down Taking amlodipine besylate tablets of Beijing New Pharmaceutical Co., Ltd as an example, after winning the bid, the price of one kind of API rose from 1000 yuan / kg to 1700 yuan / kg, and the production cost continued to rise The enterprise could only compress the cost from management to maintain the price of 0.148 yuan / tablet at the time of selection In fact, there is more than one kind of API in the industry After many pharmaceutical enterprises win the bid, there is a situation that the corresponding enterprises of some kind of API raise the price of the winning varieties of API It is urgent to solve the monopoly problem of APIs In fact, in order to break the monopoly situation, China's relevant departments have strengthened anti-monopoly law enforcement in the field of APIs in recent years, and constantly cracked down on monopoly price rise and other monopoly behaviors In addition, some pharmaceutical enterprises have also carried out self-sufficient supply and production of APIs For example, some enterprises choose to build their own API production and realize the integration of API preparation In general, the purpose of volume purchase is mainly to reduce the price of drugs and improve the quality of drugs This requires not only the efforts of pharmaceutical enterprises, but also the support and supervision of all walks of life For drug manufacturers, as a consumer oriented enterprise, they need to comply with the requirements of production, strengthen management from the source, and ensure the quality and safety of drug production In the process of drug production, the monopoly of APIs and other issues need relevant departments to strengthen effective measures to ensure the normal supply chain of APIs.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.